# How a laboratory identified a no-DAC sequence in an unknown sample

- Article ID: research-066
- Product: CJC-1295 No DAC (cjc-1295-no-dac-623, cjc-1295-no-dac-520, cjc-1295-no-dac-609)
- Canonical page: https://heritagebiolabs.com/research-library/articles/066-how-a-laboratory-identified-a-no-dac-sequence-in-an-unknown-sample
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-no-dac
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-623
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-520
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-609
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2010, 2024

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are small chains of amino acids joined by peptide bonds. Some act as signals, and the order of their amino acids gives each chain a chemical signature. CJC-1295 No DAC commonly names Mod GRF (1–29), an engineered version of the first 29 amino acids of growth hormone–releasing hormone (GHRH). How can a laboratory establish that an unknown preparation contains a peptide consistent with that description? [1]

No recent primary report of this exact identification was found. In an older investigation, published in 2010, a Norwegian laboratory analyzed an unknown preparation using liquid chromatography and high-resolution tandem mass spectrometry. The first technique separates components in a sample. The second measures the mass of a molecule and of pieces produced by breaking it apart in the instrument. The investigators found a 29-amino-acid chain with an amide at its end and used the fragments to propose its sequence. [2]

The FDA's later briefing noted that the sample lacked the drug affinity complex (DAC), an attachment that distinguishes the longer-acting form. The agency found the reported mass and formula consistent with the no-DAC free base, while the paper left the salt form unspecified. This is an example of why the investigators' measured structure tells a reader more than the shorthand name in the paper's title. [1, 2]

The laboratory report identifies what the researchers detected in a particular sample. It describes a chemical analysis, with no patients or tests of how the material affects growth hormone release. Other samples, even if they carry the same label, would need their own identity testing. The result gives researchers a way to think about what a product label means when chemical evidence is available to check it. [1, 2]

## Sources

1. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>
2. Henninge J et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis (publication 2010-12-10). <https://pubmed.ncbi.nlm.nih.gov/21204297/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 014 - CJC-1295 No DAC and CJC-1295 With DAC.docx; article 66; content SHA-256 b756d7d7000ccd7edeba72eebc78dad608e4a5f6ac4193814bd8469de53fabed.
